Coulomb controlled Iontophoresis of Carboplatin in the treatment of the transgenic murine retinoblastoma

(Coulomb-kontrollierte Iontophorese von Carboplatin zur Behandlung des Retinoblastoms am transgenetischen Mausmodell)

Zur Erlangung des akademischen Grades Doctor medicinae (Dr. med.)

vorgelegt der Medizinischen Fakultät Charité-Universitätsmedizin Berlin

von

Monika Voigt

aus Berlin
Dekane: Prof. Dr. med. Martin Paul

Gutachter: 1. Prof. Dr. Dr. (F) Peter Rieck
2. Ao. Univ.-Prof. Dr. Martina Kralinger
3. Prof. Dr. Patrick de Potter

Datum der Promotion: 10. 11. 2006
# 1. INTRODUCTION

## 1.1. Iontophoresis in Drug Delivery

1.1.1. History
1.1.2. Basis
1.1.3. Theory
1.1.4. Factors affecting iontophoretic transport
1.1.5. Pathways
1.1.6. Advantages
1.1.7. Risks and disadvantages
1.1.8. Units/Devices

## 1.2. Retinoblastoma

1.2.1. Cell and molecular biology of the retinoblastoma
1.2.2. Diagnosis
1.2.3. Classification of retinoblastoma
1.2.4. Management of retinoblastoma

# 2. AIM OF THE STUDY

# 3. MATERIALS AND METHODS

## 3.1. Coulomb-Controlled Iontophoresis device

## 3.2. Retinoblastoma Model

## 3.3. Animals

- 3.3.1. Rabbits
- 3.3.2. Mice

## 3.4. Treatment Modalities

- 3.4.1. Subconjunctival carboplatin injections in rabbit eyes
- 3.4.2 CCI delivery of carboplatin in rabbit eyes
- 3.4.3. Intravenous delivery of carboplatin in rabbit eyes
- 3.4.4. Repetitive CCI treatments on rabbit eyes – safety study
- 3.4.5. CCI treatment parameter evaluation on mice eye
- 3.4.6 Repetitive CCI treatments in transgenic retinoblastoma mice

## 3.5. Analyses Modalities

- 3.5.1. Rabbit ocular tissue dissection and preparation
- 3.5.2. Electrothermal atomic absorption spectroscopy (ET-AAS)
- 3.5.3. Electroretinography – ERG
- 3.5.4. Histopathologic evaluation of rabbits and mice eyes
3.6. Statistical Analysis

3.6.1. Pharmacokinetic study performed on rabbits
3.6.2. Tumor control analysis on transgenic mice

4. RESULTS

4.1. Results of treatments performed on rabbits

4.1.1. Pharmacokinetics of carboplatin in the rabbit
4.1.2. ERG results on rabbit eyes after repetitive CCI application
4.1.3. Histopathology of repetitively CCI treated rabbit eyes

4.2. Results of treatments performed on transgenic mice

4.2.1. Histopathology of repetitively CCI treated mice eyes
4.2.2. Iontophoretic treatment of transgenic mice

5. DISCUSSION

6. SUMMARY

7. GERMAN SHORTREPORT-KURZFASSUNG

7.1. Einleitung
7.2. Material und Methoden
7.3. Ergebnisse
7.4. Diskussion

8. REFERENCES

9. CURRICULUM VITAE

10. ACKNOWLEDGEMENT
9. CURRICULUM VITAE

Monika Voigt
DOB: 17.11.1970
Place of Birth: Berlin
Nationality: German
Marital status: married

„Mein Lebenslauf wird aus Datenschutzgründen in der elektronischen Version meiner Arbeit nicht mit veröffentlicht.“
10. ACKNOWLEDGEMENT

I would like to specially thank **PD Dr. Dr. PETER RIECK** and **PROF. Dr. Dr. CHRISTIAN HARTMANN** for having given me the unique opportunity of doing research in the field of ophthalmology in such remarkable places like the Laboratoires du développement, vieillissement et pathologie de la rétine unité INSERM U-450, the Laboratoire de Recherches ophtalmologiques Hôpital Hôtel Dieu Unité INSERM U- 86, Paris France and the Bascom Palmer Eye Institute Miami, Florida.

Through the long period of my research they were always of tremendous help, not only concerning the scientific advice but as well in the creation and guidance of my medical thesis.

My research fellowship at the Laboratoires du développement, vieillissement et pathologie de la rétine unité INSERM U-450 and Laboratoire de Recherches ophtalmologiques Hôpital Hôtel Dieu Unité INSERM U-86, Paris France was the foundation-stone for my further scientific and clinical carrier. My work in Paris was marked by the exceptional help, support and cooperation of **Dr. FRANCINE BEHAR-COHEN (MD, Ph.D)** and **Dr. YVES COURTOIS (Ph.D)**.

Without their initiative my fellowship in the United States would have been unimaginable.

Through the financial support by the DAAD my fellowship at the Bascom Palmer Eye Institute Miami, Florida could come to reality.

My work at the Ophthalmic Biophysics Center (OBC) Bascom Palmer Eye Institute Miami, Florida was an extraordinary scientific, social and cultural experience thanks to **JEAN-MARIE PAREL (Ph.D)** and the **whole team of the OBC**.

Finally I would like to pay my special regards to **TIMOTHY G. MURRAY, M.D** under whom I had the pleasure to work at the **LABORATORY FOR OCULAR ONCOLOGY** and who made the realization of this research project possible.

Furthermore I would like to thank **BRANDY HAYDEN** who was an exceptional colleague.
Eidesstattliche Erklärung


Monika Voigt
Objective: Retinoblastoma is the most common intraocular malignancy in children. Recently, the management of retinoblastoma has evolved away from radical aggressive treatments such as enucleation and external beam radiation, towards more focal, conservative treatments or moderate, combined treatment modalities. The aim of this study was to characterize the pharmacokinetics and toxicity of systemic versus focal subconjunctival and transscleral Coulomb controlled iontophoresis (CCI) of carboplatin administration in the rabbit eye. The next step was to evaluate the efficacy and the dose response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of murine transgenic hereditary retinoblastoma.

Methods: Pharmacological distribution of carboplatin was examined in New Zealand White (NZW) rabbits following a single intravenous infusion of carboplatin (18.7mg/kg body weight), a single subconjunctival carboplatin injection (5.0mg/400µl), or a single application of carboplatin delivered with CCI at 5mA/cm² for 20min treatment duration (14mg/ml carboplatin solution). Following each treatment, animals were euthanized and eyes were obtained at either 1, 2, 6 or 24hrs post treatment. Six animals per time point were treated to ensure statistical significance. Right eyes were treated, left eyes served as controls. Atomic absorption spectroscopy analysis was used to determine the carboplatin levels in the blood plasma and ocular tissues.

Twelve adult NZW were used for histopathological and functional toxicity evaluation. The rabbits underwent 6 serial iontophoretic treatments (20min at 2.5mA) of either balanced salt solution (BSS) or carboplatin (14mg/ml) administered to the right eye at 72-hour intervals. The left eyes served as untreated controls. ERGs were recorded prior to the initial treatment, than at 48hrs after the 2nd treatment, and 4 weeks post final treatment. All eyes were examined clinically following each CCI application.

Fifty-four 6 weeks old SV-40 transgenic mice underwent six, serial transcorneoscleral iontophoretic treatments (2.57mA/cm², 5min) with carboplatin. Forty-four animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14mg/ml with or without current. Ten control mice underwent a treatment with balanced salt solution. Coulomb controlled iontophoresis treatment parameters include current density and charge application times were evaluated in 8 animals. Experimental and control eyes were examined for toxicity preceding each application. All eyes were obtained at 16 weeks of age for histopathological evaluation.

Results: Determination of carboplatin concentrations via atomic absorption spectroscopy in the retina, choroid, vitreous humor, and optic nerve following subconjunctival injection and iontophoretic carboplatin delivery revealed significantly higher levels than those achieved with systemic administration. Peak levels of carboplatin in the retina were determined to be
53.68ng/mg following subconjunctival, 38.0ng/mg post CCI-delivery and 14ng/mg after intravenous administration at 1hour post treatment. Concentrations in the vitreous humor following treatments peaked at differing times: 1hr post subconjunctival injection (4560ng/ml), 6hrs post CCI delivery (1955ng/ml) and 6hrs post intravenous delivery (1220ng/ml). Carboplatin concentrations in the blood plasma were found to be significantly higher following intravenous delivery with a concentration of 6222ng/ml at 1hour, compared to concentration of 182ng/ml and 261ng/ml at 1hour for subconjunctival and iontophoretic drug delivery.

Light microscopy showed no histopathologic alterations in eyes treated with single or repetitive CCI carboplatin. ERGs revealed no depression in the a- or b-wave amplitude or alteration in the implicit times of the treated eyes.

A dose–dependent inhibition of intraocular tumor was observed following repetitive iontophoretic treatment. None of the experimental eyes treated at carboplatin concentrations of 1.4mg/ml demonstrated complete tumor control. At concentrations of 7mg/ml the treated eyes exhibited tumor control of 50 %. All eyes treated with 14mg/ml showed complete tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations less than 10mg/ml. At 14mg/ml all of the treated eyes revealed corneal damage.

**Conclusions:** Focal administration of carboplatin utilizing subconjunctival or CCI, effectively transmits this chemotherapeutic drug into the target tissues of retina, choroid, vitreous and optic nerve. This data suggests local carboplatin delivery may be effective and well tolerated in the treatment of human retinoblastoma by increasing the intra-orbital carboplatin concentration while decreasing systemic exposure to this cytotoxic drug.

Furthermore repetitive CCI administration demonstrated no signs of ocular toxicity and may present an alternative method to repetitive intravenous carboplatin administration.

Transcorneoscleral Coulomb controlled iontophoretic delivery of carboplatin safely and effectively controls intraocular retinoblastoma in a dose dependent manner in this murine model of retinoblastoma. Topical non-invasive ocular iontophoretic administration of carboplatin chemotherapy may be advantageous in the treatment of intraocular pediatric retinoblastoma in comparison to systemically applied chemotherapy.